Raphael Pharmaceutical Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Note · For the year ended December 31, | |||
|---|---|---|---|
| 2023 · 2022 | |||
| Research and development expenses | 9a | $569 | $1,178 |
| General and administrative expenses | 9b | 703 | 2,139 |
| Operating loss | 1,272 | 3,317 | |
| Total financial expense, net | 9c | 12 | 41 |
| Net loss and comprehensive loss | 1,284 | 3,358 | |
| Basic and diluted net loss per share | 0.07 | 0.23 | |
| Weighted average number of common shares used in computing basic and diluted net loss per share | 16,716,905 | 14,341,518 | |
The accompanying notes are an integral part of the condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.